Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Lysergic acid diethylamide (LSD) is a classic serotonergic psychedelic acting on the
serotonin 5-HT2A receptor. LSD is used recreationally and in psychiatric research. First
studies suggest efficacy in psychiatric disorders, such as depression and anxiety. SSRIs like
paroxetine are first-line treatments for depression and anxiety disorders. Paroxetine acts as
a serotonin transporter (SERT) inhibitor. However, the link between this mechanism and its
positive effects on mood remains to be established. Several studies suggest a possible
downregulation of postsynaptic serotonin (5-HT) receptors such as the 5-HT2A receptor. The
aim of the study is to assess whether SERT inhibition reduces expression of the gene coding
for the 5-HT2A receptor and the response to LSD.